scispace - formally typeset
Search or ask a question

Showing papers in "Vaccine in 2001"


Journal ArticleDOI
14 May 2001-Vaccine
TL;DR: In this article, a preclinical and human vaccine studies indicate that, although neonatal immunisation does not generally lead to rapid and strong antibody responses, it may result in an efficient immunological priming, which can serve as an excellent basis for future responses.

596 citations


Journal ArticleDOI
15 Oct 2001-Vaccine
TL;DR: Early post-licensure efficacy estimates for toddlers and teenagers validate the serological criteria used for licensure and set a precedent for other meningococcal conjugate polysaccharide vaccines.

469 citations


Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: New generation of adjuvants are based on a new concept called 'immunosol' and stem from the association of nanoparticles with a new immunostimulant, which can be used when emulsions are not suitable to obtain a good balance between safety and immunogenicity.

411 citations


Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: The complete genomic sequence of a human pathogen represents a new unexploited field, to be used for the design of novel vaccines and antimicrobial drugs and this approach was named "reverse vaccinology".

408 citations


Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: The addition of MF59 to subunit influenza vaccines enhances significantly the immune response in elderly subjects without causing clinically important changes in the safety profile of the influenza vaccine.

366 citations


Journal ArticleDOI
08 Feb 2001-Vaccine
TL;DR: It is suggested that baculovirus-expressed H5 HA can induce functional antibody in individuals who have not had prior exposure to H5 viruses, but that further studies to improve the immunogenicity of the vaccine are needed.

351 citations


Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: These LTK63 and LTR72 mutants are safe adjuvants to enhance the immunogenicity of vaccines at the mucosal level, and will be tested soon in humans.

334 citations


Journal ArticleDOI
14 Sep 2001-Vaccine
TL;DR: A serological correlate of vaccine-induced immunity was identified in the rabbit model of inhalational anthrax and antibody levels to PA at both 6 and 10 weeks were significant predictors of survival.

267 citations


Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: This work expresses the B-subunit of Escherichia coli heat-labile enterotoxin and the spike protein of swine transmissible gastroenteritis virus at high levels in corn, and demonstrates that these antigens delivered in the seed elicit protective immune responses.

257 citations


Journal ArticleDOI
08 Feb 2001-Vaccine
TL;DR: Among the available approaches to stimulate efficient mucosal responses, the use of bacterial carriers to deliver vaccine antigens, probably, constitutes one of the most successful strategies and the potential and limitations of themost extensively studied bacterial carrier systems will be discussed.

255 citations


Journal ArticleDOI
Maria Pau1, C. Ophorst1, Martin H. Koldijk1, G. Schouten1, M. Mehtali1, F. Uytdehaag1 
21 Mar 2001-Vaccine
TL;DR: A cell line-based production system that could replace eggs in the production of influenza virus vaccines in a pandemic proof fashion is presented.

Journal ArticleDOI
12 Dec 2001-Vaccine
TL;DR: Overall, the inactivated virus elicited a much greater magnitude of immune response than the subunit vaccines, including total IgG, all four IgG subtypes, and T-helper-cell responses; these antibodies were shown to be protective against lethal infection when passively transferred to susceptible newborn mice.

Journal ArticleDOI
30 Apr 2001-Vaccine
TL;DR: The AvP live attenuated tetravalent d Dengue vaccine was most reactogenic, and preferential replication of dengue-3 virus may have affected its infectivity and immunogenicity.

Journal ArticleDOI
14 Jun 2001-Vaccine
TL;DR: The data from the earlier study were reanalysed and the results do not support the hypothesis that MMR vaccines cause autism, and provide further evidence against a causal association between MMR vaccination and autism.

Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: This paper will examine the current anti-vaccine movement and provide current examples, and a review of suggestions for dealing with the anti- vaccines movement will be presented.

Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: TBVs against the two major species of human malaria, Plasmodium falciparum and P. vivax, are under development and testing is in progress with clinical grade material in humans.

Journal ArticleDOI
12 Oct 2001-Vaccine
TL;DR: The type and the dose of cytokine genes injected into chickens influence the quality of the local immune response to DNA vaccination against coccidiosis, and Flow cytometric analysis of duodenum intraepithelial lymphocytes showed chickens that received the pcDNA3-1E vaccine simultaneously with the IL-8 or IL-15 genes had significantly increased CD3 + cells.

Journal ArticleDOI
30 Apr 2001-Vaccine
TL;DR: Results indicate that liposome-mediated DNA immunisation is more effective than the use of naked DNA, and suggest that the presence of fusogenic phosphatidylethanolamine in DRV in conjunction with a low-melting phosph atidylcholine and an appropriate content of cationic lipid might contribute to more effective liposomal DNA vaccines.

Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: This paper reviews recent progress in supplementing DNA vaccines with plasmids encoding cytokines and targeting the Ag encoded by DNA vaccine through genetically fusing the Ag to molecules binding cell surface receptors and possible mechanisms responsible for the observed effects.

Journal ArticleDOI
30 Apr 2001-Vaccine
TL;DR: It is demonstrated that, although AVA confers variable protection against different B. anthracis isolates in guinea pigs, it is highly protective against these same isolate in both rabbits and rhesus macaques.

Journal ArticleDOI
14 Jun 2001-Vaccine
TL;DR: The data suggest that MVA can safely be used as a basis for recombinant human vaccines, and that it is also safe for use in immunocompromised individuals.

Journal ArticleDOI
30 Apr 2001-Vaccine
TL;DR: Since both the health and economic burden are high, vaccination of the elderly is expected to be cost-effective under most scenarios, and the attractiveness of immunisation increasing with age due to the increased burden of disease in the very elderly.

Journal ArticleDOI
20 Jul 2001-Vaccine
TL;DR: A sub-unit vaccine based on the F1- and V-antigens is highly effective against both bubonic and pneumonic plague, when tested in animal models of disease.

Journal ArticleDOI
14 Aug 2001-Vaccine
TL;DR: Using EpiMatrix, BlastiMer, and Patent-Blast, the list of putative Mtb epitopes to be tested in vitro was narrowed from 1600000 to 3000, a 99.8% reduction.

Journal ArticleDOI
14 Aug 2001-Vaccine
TL;DR: Mice immunised with lipopolysaccharide from Francisella tularensis were protected against challenge with the live vaccine strain (LVS), however, when similarly immunised mice were challenged using the fully virulent F. tularentic strain Schu4, only an increase in the time to death was observed.

Journal ArticleDOI
14 Sep 2001-Vaccine
TL;DR: A meta-analysis aims at combining evidence from randomized trials of PPV assessing its efficacy in preventing Streptococcus pneumoniae related diseases in immunocompetent adults, finding that PPV prevents definite pneumococcal pneumonia, but not all-cause pneumonia or death.

Journal ArticleDOI
14 May 2001-Vaccine
TL;DR: It is found that solid carriers composed of dextran with a positive charge are the most suitable carriers for the large-scale growth of influenza A virus in MDCK cells using serum-free media.

Journal ArticleDOI
21 Mar 2001-Vaccine
TL;DR: Although jet injection appears to provoke less anxiety and cause less immediate pain, studies also indicate a somewhat greater incidence of delayed local reactogenicity including soreness and edema and other measures to prevent or rapidly treat other common adverse events have been shown effective and should be considered as well.

Journal ArticleDOI
08 Jan 2001-Vaccine
TL;DR: The precise nature of natural immunity to meningococci remains unknown, although a complex interaction between the organism and nasopharyngeal mucosal barrier, innate immune mechanisms and acquired immunity is involved.

Journal ArticleDOI
14 Sep 2001-Vaccine
TL;DR: It is demonstrated that multiepitope DNA vaccines can be engineered to enhance CTL immunogenicity by increasing processing efficiency and the effect on Immunogenicity could be ascribed to modulation of processing efficiency.